secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vor Biopharma Inc. (VOR)
CIK:        0001817229
Form:       8-K
Filed at:   2024-05-02T23:59:59+00:00
Accession:  0001193125-24-129357
Event type: leadership
Sentiment:  positive
Materiality: 0.40
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vor Bio appoints Blueprint R&D President Fouad Namouni to Board of Directors
----------------------------------------------------------------------------

- Appointed independent Class II director effective April 30, 2024; term until 2026 annual meeting.
- Dr. Namouni has over 20 years oncology drug development; currently President of R&D at Blueprint Medicines.
- Receives standard non-employee director compensation: $40,000 cash retainer plus 60,000 stock option.
- Company highlights his experience in cell/genome engineering for acute myeloid leukemia pipeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817229/000119312524129357/0001193125-24-129357-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817229/000119312524129357/d801460d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-129357

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer